Tag archive for ‘CF101’

Cipher Pharmaceuticals acquires Canadian rights from Israeli Can-Fite for psoriasis, rheumatoid arthritis treatment

  Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Israeli Can-Fite Biopharma (NYSE MKT: CANF) (TASE: More...

Jewish Business News On Tuesday, February 17th, 2015

Can-Fite Receives Notice of Allowance in US for Psoriasis Patent

Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, announced that it has received a Notice of Allowance More...

Gil Tanenbaum On Tuesday, December 30th, 2014

Israel’s Can-Fite BioPharma Moves Forward with Rheumatoid Arthritis Drug

Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, has completed the Design of the Rheumatoid Arthritis More...

Can-Fite Reports Positive Rheumatoid Arthritis Treatment Results

– The 12-week Phase IIb study involving 79 patients with active rheumatoid arthritis met all its primary efficacy endpoints. – Can-Fite BioPharma Ltd. (TASE:CFBI; Bulletin Board:CANFY)  reports More...

Jewish Business News Service On Wednesday, November 6th, 2013

CanFite Wins U.S. Patent For The Reduction Of Intraocular Pressure

– Can-Fite BioPharma Ltd. (TASE: CFBI), (OTCQB: CANFY) and its subsidiary, OphthaliX Inc. (OTCQB: OPLI), jointly announced today that the U.S. Patent and Trademark Office granted a U.S. patent More...

Wordpress site Developed by Fixing WordPress Problems